Center for Clinical Investigation (CIC1436)/CARDIOMET, Rangueil University Hospital, Toulouse, France.
University of Toulouse III, Toulouse, France.
Cardiology. 2024;149(3):217-224. doi: 10.1159/000537816. Epub 2024 Mar 2.
Acute myocardial infarction (AMI) is a main contributor of sudden cardiac death worldwide. The discovery of new biomarkers that can improve AMI risk prediction meets a major clinical need for the identification of high-risk patients and the tailoring of medical treatment. Previously, we reported that autophagy a highly conserved catabolic mechanism for intracellular degradation of cellular components is involved in atherosclerotic plaque phenotype and cardiac pathological remodeling. The crucial role of autophagy in the normal and diseased heart has been well described, and its activation functions as a pro-survival process in response to myocardial ischemia. However, autophagy is dysregulated in ischemia/reperfusion injury, thus promoting necrotic or apoptotic cardiac cell death. Very few studies have focused on the plasma levels of autophagy markers in cardiovascular disease patients, even though they could be companion biomarkers of AMI injury. The aims of the present study were to evaluate (1) whether variations in plasma levels of two key autophagy regulators autophagy-related gene 5 (ATG5) and Beclin 1 (the mammalian yeast ortholog Atg6/Vps30) are associated with AMI and (2) their potential for predicting AMI risk.
The case-control study population included AMI patients (n = 100) and control subjects (n = 99) at high cardiovascular risk but without known coronary disease. Plasma levels of ATG5 and Beclin 1 were measured in the whole population study by enzyme-linked immunosorbent assay.
Multivariate analyses adjusted on common cardiovascular factors and medical treatments, and receiver operating characteristic curves demonstrated that ATG5 and Beclin 1 levels were inversely associated with AMI and provided original biomarkers for AMI risk prediction.
Plasma levels of autophagy regulators ATG5 and Beclin 1 represent relevant candidate biomarkers associated with AMI.
急性心肌梗死(AMI)是全球范围内导致心源性猝死的主要原因。发现新的生物标志物,以提高 AMI 风险预测,满足了识别高危患者和调整治疗的重要临床需求。此前,我们报道自噬是一种用于细胞内降解细胞成分的高度保守的分解代谢机制,与动脉粥样硬化斑块表型和心脏病理重塑有关。自噬在正常和病变心脏中的关键作用已得到充分描述,其激活可作为心肌缺血的一种生存促进过程。然而,自噬在缺血/再灌注损伤中失调,从而促进坏死或凋亡的心脏细胞死亡。很少有研究关注心血管疾病患者的自噬标志物血浆水平,尽管它们可能是 AMI 损伤的伴随生物标志物。本研究的目的是评估(1)两种关键自噬调节剂自噬相关基因 5(ATG5)和 Beclin 1(哺乳动物酵母同源物 Atg6/Vps30)的血浆水平变化是否与 AMI 相关,以及(2)它们预测 AMI 风险的潜力。
病例对照研究人群包括高心血管风险但无已知冠心病的 AMI 患者(n=100)和对照受试者(n=99)。通过酶联免疫吸附试验在全人群研究中测量 ATG5 和 Beclin 1 的血浆水平。
多变量分析调整了常见心血管因素和药物治疗,接受者操作特征曲线表明 ATG5 和 Beclin 1 水平与 AMI 呈负相关,并为 AMI 风险预测提供了原始生物标志物。
自噬调节剂 ATG5 和 Beclin 1 的血浆水平代表与 AMI 相关的相关候选生物标志物。